Incruse Ellipta (previously Incruse) Eiropas Savienība - latviešu - EMA (European Medicines Agency)

incruse ellipta (previously incruse)

glaxosmithkline (ireland) limited - umeclidinium bromide - plaušu slimība, hroniska obstruktīva - zāles obstruktīvu elpceļu slimību, - norādīts kā uzturēšanas bronhodilatatora terapija simptomu mazināšanai pieaugušiem pacientiem ar hronisku obstruktīvu plaušu slimību (hops).

Crusia 10000 SV (100 mg)/1 ml šķīdums injekcijām pilnšļircē Latvija - latviešu - Zāļu valsts aģentūra

crusia 10000 sv (100 mg)/1 ml šķīdums injekcijām pilnšļircē

laboratorios farmaceuticos rovi, s.a., spain - enoksaparīna nātrija sāls - Šķīdums injekcijām pilnšļircē - 10000 sv (100 mg)/1 ml

Crusia 4000 SV (40 mg)/0,4 ml šķīdums injekcijām pilnšļircē Latvija - latviešu - Zāļu valsts aģentūra

crusia 4000 sv (40 mg)/0,4 ml šķīdums injekcijām pilnšļircē

laboratorios farmaceuticos rovi, s.a., spain - enoksaparīna nātrija sāls - Šķīdums injekcijām pilnšļircē - 4000 sv (40 mg)/0,4 ml

Crusia 8000 SV (80 mg)/0,8 ml šķīdums injekcijām pilnšļircē Latvija - latviešu - Zāļu valsts aģentūra

crusia 8000 sv (80 mg)/0,8 ml šķīdums injekcijām pilnšļircē

laboratorios farmaceuticos rovi, s.a., spain - enoksaparīna nātrija sāls - Šķīdums injekcijām pilnšļircē - 8000 sv (80 mg)/0,8 ml

Crusia 6000 SV (60 mg)/0,6 ml šķīdums injekcijām pilnšļircē Latvija - latviešu - Zāļu valsts aģentūra

crusia 6000 sv (60 mg)/0,6 ml šķīdums injekcijām pilnšļircē

laboratorios farmaceuticos rovi, s.a., spain - enoksaparīna nātrija sāls - Šķīdums injekcijām pilnšļircē - 6000 sv (60 mg)/0,6 ml

Crusia 2000 SV (20 mg)/0,2 ml šķīdums injekcijām pilnšļircē Latvija - latviešu - Zāļu valsts aģentūra

crusia 2000 sv (20 mg)/0,2 ml šķīdums injekcijām pilnšļircē

laboratorios farmaceuticos rovi, s.a., spain - enoksaparīna nātrija sāls - Šķīdums injekcijām pilnšļircē - 2000 sv (20 mg)/0,2 ml

CRUSH Energy & Endurance (2023.) pulveris Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

crush energy & endurance (2023.) pulveris

pulveris

CRUSH (2023.) pulveris Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

crush (2023.) pulveris

pulveris

Memo-Prime (2022.) kapsula, augu izcelsmes kapsulas Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

memo-prime (2022.) kapsula, augu izcelsmes kapsulas

kapsula, augu izcelsmes kapsulas

Tyenne Eiropas Savienība - latviešu - EMA (European Medicines Agency)

tyenne

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imūnsupresanti - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.